Myriad Genetics (MYGN) Stock Price, News & Analysis

Company Overview

Myriad Genetics, Inc., headquartered in Salt Lake City, Utah, is a global leader in molecular diagnostics committed to transforming health care through predictive medicine. Founded in 1991, the company has grown from its early focus on hereditary cancer testing to a broad portfolio of genetic assays that inform disease risk assessment, diagnosis and treatment decisions. Myriad’s mission is to provide clinicians and patients with accurate, actionable insights to guide personalized care.

Myriad’s core offerings include hereditary cancer risk tests such as BRACAnalysis CDx, which evaluates BRCA1 and BRCA2 gene mutations linked to breast and ovarian cancer, and myRisk, a multi-gene panel that assesses predisposition to a range of cancers. Beyond oncology, the company markets Prolaris, a prognostic test for prostate cancer, and EndoPredict, which predicts breast cancer recurrence risk. In the neurology and psychiatry space, Myriad’s GeneSight pharmacogenomic test helps clinicians tailor medication choices for patients with depression, anxiety and related disorders.

With operations spanning North America, Europe, Asia Pacific and Latin America, Myriad serves a diverse network of hospitals, academic centers and reference laboratories. The company engages in strategic collaborations with pharmaceutical firms and research institutions to develop companion diagnostics and support clinical trials. Under the leadership of President and CEO Mark T. Capone, Myriad continues to invest in research and technology, aiming to expand its test menu and bring new genomic solutions to markets worldwide.

Key Stats

• Today's Range: $5.25 to $5.61
• 50-Day Range: $3.84 to $7.70
• 52-Week Range: $3.81 to $29.30
• Volume: 1.38 million shs
• Average Volume: 1.26 million shs
• Market Capitalization: $487.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.38
• Consensus Rating: Hold

Myriad Genetics Stock Analysis - MarketRank™

Myriad Genetics scored higher than 82% of companies evaluated by MarketBeat, and ranked 166th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 10 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Myriad Genetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Myriad Genetics are expected to remain at ($0.30) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myriad Genetics is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myriad Genetics is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myriad Genetics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.31% of the float of Myriad Genetics has been sold short.

Short Interest Ratio / Days to Cover

Myriad Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myriad Genetics has recently decreased by 4.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myriad Genetics does not currently pay a dividend.

Dividend Growth

Myriad Genetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

9.31% of the float of Myriad Genetics has been sold short.

Short Interest Ratio / Days to Cover

Myriad Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myriad Genetics has recently decreased by 4.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Myriad Genetics this week, compared to 8 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Myriad Genetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Myriad Genetics is held by insiders.

Percentage Held by Institutions

99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MYGN Stock Analysis - Frequently Asked Questions

How have MYGN shares performed this year?

Myriad Genetics' stock was trading at $13.71 at the beginning of the year. Since then, MYGN shares have decreased by 61.4% and is now trading at $5.29.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) issued its earnings results on Tuesday, May, 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02. The firm's revenue for the quarter was down 33.6% on a year-over-year basis.
Read the conference call transcript.

Does Myriad Genetics have any subsidiaries?

The following companies are subsidiaries of Myriad Genetics: Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MYGN
• CIK: 899923
• Web: www.myriad.com
• Phone: (801) 584-3600
• Fax: 801-584-3640
• Employees: 2,700
• Year Founded: 1991

Price Target and Rating

• Average Stock Price Target: $14.38
• High Stock Price Target: $30.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +171.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.30 million
• Net Margins: -12.20%
• Pretax Margin: -15.28%
• Return on Equity: -4.95%
• Return on Assets: -3.39%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 1.90
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $837.60 million
• Price / Sales: 0.58
• Cash Flow: $0.94 per share
• Price / Cash Flow: 5.60
• Book Value: $7.70 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 92,180,000
• Free Float: 90,241,000
• Market Cap: $487.63 million
• Optionable: Optionable
• Beta: 1.91